5-氯-2-(氯甲基)嘧啶 | 944902-28-7

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-氯-2-(氯甲基)嘧啶
• 英文名称: 5-chloro-2-(chloromethyl)pyrimidine
• CAS: 944902-28-7
• 化学式: C₅H₄Cl₂N₂
• mdl: MFCD10697073
• 分子量: 163.006
• InChiKey: QWCRLUJTUHEVAU-UHFFFAOYSA-N

物化性质

• 沸点：
  212.2±20.0 °C(Predicted)
• 密度：
  1.410±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  5-氯-2-(氯甲基)嘧啶 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium phosphate 、 二乙胺基三氟化硫 、 potassium carbonate 、 potassium iodide 作用下， 以 2-甲基四氢呋喃 、 二氯甲烷 、 乙腈 为溶剂， 反应 20.0h， 生成 5-chloro-2-[[2-(6-chloro-5-fluoro-3-pyridyl)-4-(difluoromethyl)imidazol-1-yl]methyl]pyrimidine
  参考文献：
  名称：

  [EN] HERBICIDAL IMIDAZOLE COMPOUNDS
  [FR] COMPOSÉS IMIDAZOLE HERBICIDES

  摘要：

  The present invention relates to compounds of Formula (I) or an agronomically acceptable salt of said compounds wherein Q, R1and R2are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I) and to the use of compounds of Formula (I) for controlling weeds, in particular in crops of useful plants.

  公开号：

  WO2023066783A1

文献信息

• EGFR KINASE KNOCKDOWN VIA ELECTROPHILICALLY ENHANCED INHIBITORS
  申请人：MILLER Richard

  公开号：US20100144705A1

  公开（公告）日：2010-06-10

  Provided herein are electrophilically enhanced kinase inhibitors. Also provided herein are methods of making and utilizing the same.

  本文提供了电亲性增强激酶抑制剂。本文还提供了制备和利用这些抑制剂的方法。
• [EN] FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS<br/>[FR] BENZOXAZÉPINONES FUSIONNÉS EN TANT QUE MODULATEURS DES CANAUX IONIQUES
  申请人：GILEAD SCIENCES INC

  公开号：WO2013006485A1

  公开（公告）日：2013-01-10

  The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Z1, Z2, Z3, Z4, X, Y, R2, R3 and R4 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及的化合物是钠通道抑制剂，可用于治疗各种疾病状态，包括心血管疾病和糖尿病。在特定实施例中，化合物的结构由公式I给出：其中Z1、Z2、Z3、Z4、X、Y、R2、R3和R4如本文所述，以及制备和使用该化合物的方法，以及含有该化合物的药物组合物。
• FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
  申请人：Gilead Sciences, Inc.

  公开号：US20130184255A1

  公开（公告）日：2013-07-18

  The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Z 1 , Z 2 , Z 3 , Z 4 , X, Y, R 2 , R 3 and R 4 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及一种钠通道抑制剂化合物及其在治疗各种疾病状态中的应用，包括心血管疾病和糖尿病。在特定实施例中，化合物的结构由式I给出：其中Z1，Z2，Z3，Z4，X，Y，R2，R3和R4如本文所述，还涉及到制备和使用该化合物的方法以及含有该化合物的制药组合物。
• FUSED BENZOXAZEPINONES AS ION CHANNEL MODULATORS
  申请人：Gilead Sciences, Inc.

  公开号：EP2726466A1

  公开（公告）日：2014-05-07
• IMIDAZOTRIAZINONE COMPOUNDS
  申请人：Ironwood Pharmaceuticals, Inc.

  公开号：US20170327502A1

  公开（公告）日：2017-11-16

  The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9 and pharmaceutically acceptable salt thereof. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.